An in vitro or ex vivo use of miR-124, as a biomarker for screening a compound of formula, for efficacy in treating and/or preventing an inflammatory disease selected from a group consisting of: a joint inflammation disease, an inflammatory digestive tract disease, inflammatory skin disease, bronchitis and asthma; wherein formula is defined herein after wherein: Z is C or N, V is C or N, means an aromatic ring wherein V is C or N and when V is N, V is in ortho, meta or para of Z, i.e. forms respectively a pyridine, a pyridazine, a pyrimidine or a pyrazine group, R independently represent a hydrogen atom, a methyl group, a methoxy group, a trifluoromethyl group, a trifluoromethoxy group, an amino group, a halogen atom and a -O-P(=O)-(OR 3)(OR 4) group and more particularly a fluorine or chlorine atom, a trifluoromethoxy group and an amino group, Q is N or O, provided that R" does not exist when Q is O, R 3 and R 4 independently represent a hydrogen atom, Li +, Na +, K +, N + (Ra) 4 or a benzyl group, Ra represents a hydrogen atom, a (C 1 -C 5)alkyl group or a (C 3 -C 6)cycloalkyl group, n is 1, 2 or 3, n' is 1, 2 or 3, R' independently represent a hydrogen atom, a halogen atom and more particularly a fluorine or chlorine atom, an amino group, a methyl group, a -O-P(=O)-(OR 3)(OR 4) group or a group, wherein A is O or NH, m is 2 or 3 and X 1 is O, CH 2 or N-CH 3, provided that when R' is such a group, n' is 1 or 2, and when n' is 2, the other R' group is different from said group or alternatively R' independently represent a hydrogen atom, a halogen atom and more particularly a fluorine or chlorine atom, a methyl group or a group, wherein A is O or NH, m is 2 and X 1 is O, CH 2 or N-CH 3, provided that when R' is such a group, n' is 1 or 2, and when n' is 2, the other R' group is different from said group, R" is a hydrogen atom, a (C 1 -C 4)alkyl group or a group wherein m is 2 or 3 and X 1 is O, CH 2 or N-CH 3, or anyone of its pharmaceutically acceptable salt. Z is C or N, V is C or N, means an aromatic ring wherein V is C or N and when V is N, V is in ortho, meta or para of Z, i.e. forms respectively a pyridine, a pyridazine, a pyrimidine or a pyrazine group, R independently represent a hydrogen atom, a methyl group, a methoxy group, a trifluoromethyl group, a trifluoromethoxy group, an amino group, a halogen atom and a -O-P(=O)-(OR 3)(OR 4) group and more particularly a fluorine or chlorine atom, a trifluoromethoxy group and an amino group, Q is N or O, provided that R" does not exist when Q is O, R 3 and R 4 independently represent a hydrogen atom, Li +, Na +, K +, N + (Ra) 4 or a benzyl group, Ra represents a hydrogen atom, a (C 1 -C 5)alkyl group or a (C 3 -C 6)cycloalkyl group, n is 1, 2 or 3, n' is 1, 2 or 3, R' independently represent a hydrogen atom, a halogen atom and more particularly a fluorine or chlorine atom, an amino group, a methyl group, a -O-P(=O)-(OR 3)(OR 4) group or a group, wherein A is O or NH, m is 2 or 3 and X 1 is O, CH 2 or N-CH 3, provided that when R' is such a group, n' is 1 or 2, and when n' is 2, the other R' group is different from said group or alternatively R' independently represent a hydrogen atom, a halogen atom and more particularly a fluorine or chlorine atom, a methyl group or a group, wherein A is O or NH, m is 2 and X 1 is O, CH 2 or N-CH 3, provided that when R' is such a group, n' is 1 or 2, and when n' is 2, the other R' group is different from said group, R" is a hydrogen atom, a (C 1 -C 4)alkyl group or a group wherein m is 2 or 3 and X 1 is O, CH 2 or N-CH 3, or anyone of its pharmaceutically acceptable salt.